SBI Securities Co. Ltd. Purchases 48,013 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB)

SBI Securities Co. Ltd. raised its position in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB - Free Report) by 221.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 69,664 shares of the biotechnology company's stock after acquiring an additional 48,013 shares during the quarter. SBI Securities Co. Ltd. owned about 0.80% of Seres Therapeutics worth $49,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of MCRB. Charles Schwab Investment Management Inc. raised its holdings in shares of Seres Therapeutics by 15.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company's stock valued at $720,000 after purchasing an additional 117,107 shares during the period. Avantax Advisory Services Inc. raised its holdings in shares of Seres Therapeutics by 170.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 28,500 shares during the period. Vontobel Holding Ltd. raised its holdings in shares of Seres Therapeutics by 15.7% during the first quarter. Vontobel Holding Ltd. now owns 1,085,966 shares of the biotechnology company's stock valued at $760,000 after purchasing an additional 147,671 shares during the period. Jane Street Group LLC raised its holdings in shares of Seres Therapeutics by 181.4% during the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock valued at $49,000 after purchasing an additional 37,866 shares during the period. Finally, Millennium Management LLC raised its holdings in shares of Seres Therapeutics by 77.2% during the fourth quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company's stock valued at $1,505,000 after purchasing an additional 788,762 shares during the period. Institutional investors own 59.34% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Chardan Capital restated a "neutral" rating and issued a $6.00 target price (up previously from $1.25) on shares of Seres Therapeutics in a report on Thursday, May 8th. Wall Street Zen upgraded shares of Seres Therapeutics from a "sell" rating to a "hold" rating in a report on Friday, May 9th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat, Seres Therapeutics currently has an average rating of "Hold" and an average price target of $73.67.

Seres Therapeutics Price Performance

Shares of NASDAQ:MCRB opened at $14.07 on Friday. The firm has a fifty day moving average price of $9.14 and a two-hundred day moving average price of $12.18. Seres Therapeutics, Inc. has a one year low of $6.53 and a one year high of $29.40. The company has a market cap of $122.83 million, a price-to-earnings ratio of -3.06 and a beta of 2.75.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($1.57). Equities research analysts expect that Seres Therapeutics, Inc. will post -0.38 EPS for the current fiscal year.

Seres Therapeutics Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.